CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.6458
5.18%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.1084
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.7358
Open* 1.6358
1-Year Change* -14.67%
Day's Range* 1.6358 - 1.8558
52 wk Range 1.43-2.79
Average Volume (10 days) 18.81K
Average Volume (3 months) 275.60K
Market Cap 27.51M
P/E Ratio -100.00K
Shares Outstanding 14.26M
Revenue 39.32M
EPS -0.17
Dividend (Yield %) N/A
Beta 0.17
Next Earnings Date Mar 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 1.7358 0.0400 2.36% 1.6958 1.7858 1.6358
Mar 26, 2024 1.6958 0.0400 2.42% 1.6558 1.8158 1.6558
Mar 25, 2024 1.7058 -0.0400 -2.29% 1.7458 1.7858 1.7058
Mar 22, 2024 1.7758 -0.0300 -1.66% 1.8058 1.8158 1.7458
Mar 21, 2024 1.7958 -0.0100 -0.55% 1.8058 1.8758 1.7658
Mar 20, 2024 1.8058 0.0300 1.69% 1.7758 1.8858 1.7658
Mar 19, 2024 1.8158 -0.2200 -10.81% 2.0358 2.0358 1.7658
Mar 18, 2024 1.8658 0.1000 5.66% 1.7658 1.9258 1.7658
Mar 15, 2024 1.7958 -0.0200 -1.10% 1.8158 1.9758 1.7658
Mar 14, 2024 1.7958 -0.0200 -1.10% 1.8158 1.8858 1.7958
Mar 13, 2024 1.7958 -0.0100 -0.55% 1.8058 1.8958 1.7958
Mar 12, 2024 1.8058 -0.1000 -5.25% 1.9058 1.9958 1.8058
Mar 11, 2024 1.9958 -0.0100 -0.50% 2.0058 2.0258 1.9558
Mar 8, 2024 2.0058 0.0000 0.00% 2.0058 2.0758 1.9958
Mar 7, 2024 2.0158 0.0000 0.00% 2.0158 2.0558 1.9958
Mar 6, 2024 1.9358 0.0200 1.04% 1.9158 1.9958 1.7958
Mar 5, 2024 1.9958 -0.0200 -0.99% 2.0158 2.0958 1.9058
Mar 4, 2024 2.0258 0.0200 1.00% 2.0058 2.1558 1.9658
Mar 1, 2024 2.1158 -0.0200 -0.94% 2.1358 2.1958 2.0258
Feb 29, 2024 2.1258 0.0000 0.00% 2.1258 2.1558 2.1258

Cumberland Events

Time (UTC) Country Event
Wednesday, April 24, 2024

Time (UTC)

14:30

Country

US

Event

Cumberland Pharmaceuticals Inc Annual Shareholders Meeting
Cumberland Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Tuesday, May 7, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Cumberland Pharmaceuticals Inc Earnings Release
Q1 2024 Cumberland Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 42.0109 35.985 37.4411 34.3883 29.3449
Revenue 42.0109 35.985 37.4411 34.3883 29.3449
Cost of Revenue, Total 9.11852 7.41125 8.45302 7.42132 6.01682
Gross Profit 32.8924 28.5738 28.9881 26.967 23.3281
Total Operating Expense 47.7159 43.6625 43.8227 43.6765 40.5179
Selling/General/Admin. Expenses, Total 26.5803 24.5604 24.9618 25.2521 24.1557
Research & Development 6.68892 5.68447 5.77383 6.86848 7.57589
Depreciation / Amortization 5.32811 4.60637 4.43412 4.13456 2.76947
Operating Income -5.70493 -7.67742 -6.3816 -9.28818 -11.173
Interest Income (Expense), Net Non-Operating -0.48759 -0.07195 -0.18828 -0.00283 0.36863
Net Income Before Taxes -5.58119 -5.56223 -6.56988 -9.291 -10.8044
Net Income After Taxes -5.65004 -5.59712 -6.62578 -9.21169 -10.821
Minority Interest 0.0798 0.09521 0.0795 0.00875 0.0757
Net Income Before Extra. Items -5.57024 -5.50191 -6.54628 -9.20294 -10.7453
Net Income -5.57024 -3.50759 -3.33941 -3.53776 -6.96307
Income Available to Common Excl. Extra. Items -5.57024 -5.50191 -6.54628 -9.20294 -10.7453
Income Available to Common Incl. Extra. Items -5.57024 -3.50759 -3.33941 -3.53776 -6.96307
Diluted Net Income -5.57024 -3.50759 -3.33941 -3.53776 -6.96307
Diluted Weighted Average Shares 14.5636 14.9048 15.1622 15.3961 15.614
Diluted EPS Excluding Extraordinary Items -0.38248 -0.36914 -0.43175 -0.59774 -0.68818
Diluted Normalized EPS -0.38248 -0.30808 -0.42318 -0.59774 -0.68818
Total Extraordinary Items 0 1.99432 3.20688 5.66518 3.78222
Unusual Expense (Income) 0 1.4 0.2 0
Other, Net 0.61133 2.18714
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 10.8889 9.22464 9.12368 11.4131 10.2992
Revenue 10.8889 9.22464 9.12368 11.4131 10.2992
Cost of Revenue, Total 1.52077 1.25026 4.45031 1.42444 1.63188
Gross Profit 9.36811 7.97438 4.67337 9.98863 8.66727
Total Operating Expense 10.866 10.7563 11.4015 11.7017 12.1457
Selling/General/Admin. Expenses, Total 7.04196 6.77631 6.88711 6.27652 6.76066
Research & Development 1.14504 1.49967 1.40584 1.71425 1.82369
Depreciation / Amortization 1.15825 1.23007 0.45822 1.48645 1.52945
Unusual Expense (Income) -1.8 0.8 0.4
Operating Income 0.02286 -1.53168 -2.2778 -0.28859 -1.84654
Interest Income (Expense), Net Non-Operating -0.13558 -0.13616 -0.13376 -0.12774 -0.12255
Net Income Before Taxes 0.86909 0.17922 -2.41156 -0.41633 -1.35777
Net Income After Taxes 0.86215 0.17229 -2.45971 -0.42323 -1.36467
Minority Interest 0.01005 0.0199 0.01899 0.01459 0.02905
Net Income Before Extra. Items 0.8722 0.19218 -2.44073 -0.40864 -1.33562
Total Extraordinary Items 0 0 0
Net Income 0.8722 0.19218 -2.44073 -0.40864 -1.33562
Income Available to Common Excl. Extra. Items 0.8722 0.19218 -2.44073 -0.40864 -1.33562
Income Available to Common Incl. Extra. Items 0.8722 0.19218 -2.44073 -0.40864 -1.33562
Diluted Net Income 0.8722 0.19218 -2.44073 -0.40864 -1.33562
Diluted Weighted Average Shares 14.5543 14.5878 14.3974 14.4775 14.6885
Diluted EPS Excluding Extraordinary Items 0.05993 0.01317 -0.16953 -0.02823 -0.09093
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.05993 0.01317 -0.25079 0.00769 -0.07323
Other, Net 0.98181 1.84707 0 0 0.61133
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 45.8702 45.688 49.9696 50.1631 59.116
Cash and Short Term Investments 19.758 27.0408 24.7538 28.2126 36.2296
Cash & Equivalents 19.758 27.0408 24.7538 28.2126 27.939
Short Term Investments 0 8.29068
Total Receivables, Net 13.1637 6.87735 12.3777 9.78146 7.84425
Accounts Receivable - Trade, Net 13.1637 6.87735 12.3777 9.78146 7.84425
Total Inventory 9.86358 8.42988 10.6382 9.41152 12.0783
Prepaid Expenses 3.08498 3.33997 2.19993 2.75746 2.96381
Total Assets 92.9252 84.4598 96.4633 104.549 112.694
Property/Plant/Equipment, Total - Net 5.50244 1.46684 2.60232 3.70837 0.77121
Property/Plant/Equipment, Total - Gross 7.58763 5.25899 6.1594 7.10269 3.89592
Accumulated Depreciation, Total -2.08519 -3.79215 -3.55709 -3.39433 -3.12471
Intangibles, Net 30.5907 23.9545 28.1183 30.9203 33.6551
Other Long Term Assets, Total 10.0478 12.4685 14.8911 18.8755 18.3675
Total Current Liabilities 28.5798 19.279 25.6674 24.1502 27.8042
Accounts Payable 10.819 9.64098 13.3963 11.9124 11.0933
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 15.5374 7.30925 9.96232 9.19241 15.0131
Total Liabilities 56.659 41.6455 49.4728 53.4264 56.8491
Total Long Term Debt 16.2 15 15 18.5 20
Long Term Debt 16.2 15 15 18.5 20
Minority Interest -0.29213 -0.21233 -0.11712 -0.03762 -0.27427
Other Liabilities, Total 12.1713 7.57886 8.92247 10.8138 9.31914
Total Equity 36.2661 42.8143 46.9905 51.1229 55.8448
Common Stock 47.475 48.4529 49.1215 49.9145 51.0986
Retained Earnings (Accumulated Deficit) -11.2088 -5.6386 -2.13101 1.2084 4.74615
Total Liabilities & Shareholders’ Equity 92.9252 84.4598 96.4633 104.549 112.694
Total Common Shares Outstanding 14.3663 14.7428 14.9884 15.2636 15.4815
Goodwill, Net 0.914 0.882 0.882 0.882 0.784
Accrued Expenses 2.22339 2.32873 2.30884 3.04538 1.69783
Other Current Assets, Total 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 41.7698 43.6741 43.8108 45.8702 49.1606
Cash and Short Term Investments 18.508 18.2491 16.3862 19.758 19.5415
Cash & Equivalents 18.508 18.2491 16.3862 19.758 19.5415
Total Receivables, Net 12.6201 12.2188 14.5291 13.1637 15.2327
Accounts Receivable - Trade, Net 12.6201 12.2188 14.5291 13.1637 15.2327
Total Inventory 8.67055 10.9284 10.18 9.86358 10.6475
Prepaid Expenses 1.97116 2.27789 2.7155 3.08498 3.73884
Total Assets 87.7509 89.3754 89.4686 92.9252 90.7766
Property/Plant/Equipment, Total - Net 7.08859 7.21589 5.27391 5.50244 0.71068
Goodwill, Net 0.914 0.914 0.914 0.914 1.93288
Intangibles, Net 27.1211 28.2698 29.3902 30.5907 29.048
Other Long Term Assets, Total 10.8575 9.30156 10.0797 10.0478 9.92435
Total Current Liabilities 27.3283 26.9591 25.7074 28.5798 25.3062
Accounts Payable 10.8181 10.912 11.2223 10.819 11.5108
Accrued Expenses 0.33429 0.32084 0.15837 0.17291 0.22961
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 16.1759 15.7262 14.3267 17.5879 13.5659
Total Liabilities 51.7594 52.2164 53.1081 56.659 52.0123
Total Long Term Debt 12.9231 13.1481 16.0723 16.2 17.7
Long Term Debt 12.9231 13.1481 16.0723 16.2 17.7
Minority Interest -0.33599 -0.32207 -0.31202 -0.29213 -0.27314
Other Liabilities, Total 11.844 12.4312 11.6404 12.1713 9.27921
Total Equity 35.9916 37.159 36.3605 36.2661 38.7643
Common Stock 47.1853 47.3034 47.3772 47.475 47.5324
Retained Earnings (Accumulated Deficit) -11.1938 -10.1445 -11.0167 -11.2088 -8.76811
Total Liabilities & Shareholders’ Equity 87.7509 89.3754 89.4686 92.9252 90.7766
Total Common Shares Outstanding 14.2179 14.331 14.43 14.3663 14.4366
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -5.65004 -3.6028 -3.4189 -3.54651 -7.03877
Cash From Operating Activities 8.4534 6.34244 5.41506 3.05636 3.11274
Cash From Operating Activities 5.32811 4.60637 4.74857 4.40418 2.9827
Deferred Taxes 0 0 0.0218 0.06541 0.08189
Non-Cash Items -1.66511 -2.84118 0.5308 0.70294 1.21426
Cash Taxes Paid 0.0033 -0.00033 -0.09149 0.01669 0.01544
Cash Interest Paid 0.52316 0.06398 0.21599 0.19866 0.09597
Changes in Working Capital 10.4404 8.18005 3.5328 1.43034 5.87267
Cash From Investing Activities -13.6745 -0.50189 -1.75779 2.29785 -27.7248
Capital Expenditures -2.07381 -0.35446 -2.11393 -1.01915 -4.27506
Other Investing Cash Flow Items, Total -11.6006 -0.14743 0.35614 3.31699 -23.4498
Cash From Financing Activities -2.06179 -3.55353 -7.11611 -5.08053 7.13817
Financing Cash Flow Items -2.20874 -2.16668 -1.76459 -0.08561 -0.38331
Issuance (Retirement) of Stock, Net -1.05304 -1.38685 -1.85153 -3.49492 -2.67852
Issuance (Retirement) of Debt, Net 1.2 0 -3.5 -1.5 10.2
Net Change in Cash -7.28285 2.28702 -3.45884 0.27368 -17.4739
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 0.17229 -5.65004 -3.19033 -2.7671 -1.40243
Cash From Operating Activities -1.41821 8.4534 4.81537 2.18004 -0.1505
Cash From Operating Activities 1.25568 5.32811 4.81663 3.27209 1.65375
Non-Cash Items -2.05105 -1.66511 -0.62674 0.05563 0.75476
Changes in Working Capital -0.79512 10.4404 3.8158 1.61942 -1.15657
Cash From Investing Activities -0.17445 -13.6745 -13.0337 -13.7145 -13.5419
Capital Expenditures -0.17445 -2.07381 -0.43304 -0.21449 -0.0419
Other Investing Cash Flow Items, Total 0 -11.6006 -12.6006 -13.5 -13.5
Cash From Financing Activities -1.77914 -2.06179 0.71904 2.7102 3.91837
Financing Cash Flow Items -1.46431 -2.20874 -1.11758 -0.50151 -0.50151
Issuance (Retirement) of Stock, Net -0.18712 -1.05304 -0.86338 -0.7883 -0.58013
Issuance (Retirement) of Debt, Net -0.12771 1.2 2.7 4 5
Net Change in Cash -3.3718 -7.28285 -7.49928 -8.82425 -9.77403
Deferred Taxes 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cumberland Company profile

About Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription products. The Company's product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection, for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and RediTrex.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cumberland Pharmaceuticals, Inc. revenues decreased 4% to $36M. Net loss before extraordinary items decreased 16% to $5.5M. Revenues reflect Acetadote segment decrease of 55% to $851K, RediTrex segment decrease of 94% to $55K. Lower net loss reflects Interest expense decrease of 63% to $98K (expense), Research and Development decrease of 2% to $5.7M (expense).

Equity composition

Common stock no par, 03/11, 100M auth., 20,432,034 issd. Insider owns approx. 37.85% .IPO:8/11/2009, 5M shares @ $17 per share by UBS Securities LLC, Jefferies & Company, Inc., Wells Fargo Securities, LLC & MorganJoseph & Co. Inc. 6/07,Stock Split 2:1.

Industry: Generic Pharmaceuticals

2525 W End Ave Ste 950
NASHVILLE
TENNESSEE 37203-1608
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

US100

18,240.70 Price
-0.210% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

70,803.40 Price
+2.670% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.63 Price
+2.520% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,222.30 Price
+1.150% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading